KARUNA THERAPEUTICS INC (KRTX)
US48576A1007 - Common Stock
Taking everything into account, KRTX scores 3 out of 10 in our fundamental rating. KRTX was compared to 588 industry peers in the Biotechnology industry. KRTX has a great financial health rating, but its profitability evaluates not so good. KRTX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year KRTX has reported negative net income.
In the past year KRTX has reported a negative cash flow from operations.
In the past 5 years KRTX always reported negative net income.
KRTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -32.46%, KRTX is doing good in the industry, outperforming 69.32% of the companies in the same industry.
The Return On Equity of KRTX (-34.58%) is better than 78.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.46% | ||
| ROE | -34.58% | ||
| ROIC | N/A |
ROA(3y)-27.82%
ROA(5y)-22.87%
ROE(3y)-29.25%
ROE(5y)-23.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for KRTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KRTX has been increased compared to 1 year ago.
KRTX has more shares outstanding than it did 5 years ago.
KRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
KRTX has an Altman-Z score of 90.95. This indicates that KRTX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 90.95, KRTX belongs to the best of the industry, outperforming 98.81% of the companies in the same industry.
KRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 90.95 |
ROIC/WACCN/A
WACC8.97%
2.3 Liquidity
KRTX has a Current Ratio of 19.31. This indicates that KRTX is financially healthy and has no problem in meeting its short term obligations.
KRTX's Current ratio of 19.31 is amongst the best of the industry. KRTX outperforms 93.56% of its industry peers.
A Quick Ratio of 19.31 indicates that KRTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 19.31, KRTX belongs to the top of the industry, outperforming 93.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.31 | ||
| Quick Ratio | 19.31 |
3. Growth
3.1 Past
The earnings per share for KRTX have decreased strongly by -34.42% in the last year.
The Revenue for KRTX has decreased by -93.89% in the past year. This is quite bad
EPS 1Y (TTM)-34.42%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-35.59%
Revenue 1Y (TTM)-93.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-100%
3.2 Future
Based on estimates for the next years, KRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.97% on average per year.
Based on estimates for the next years, KRTX will show a very strong growth in Revenue. The Revenue will grow by 331.85% on average per year.
EPS Next Y-5.2%
EPS Next 2Y13.86%
EPS Next 3Y27.79%
EPS Next 5Y32.97%
Revenue Next Year1701.02%
Revenue Next 2Y1192.99%
Revenue Next 3Y680.54%
Revenue Next 5Y331.85%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KRTX. In the last year negative earnings were reported.
Also next year KRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as KRTX's earnings are expected to grow with 27.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.86%
EPS Next 3Y27.79%
5. Dividend
5.1 Amount
No dividends for KRTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KARUNA THERAPEUTICS INC
NASDAQ:KRTX (3/15/2024, 8:00:03 PM)
After market: 329.83 0 (0%)329.83
+0.09 (+0.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.58B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.46% | ||
| ROE | -34.58% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 19.31 | ||
| Quick Ratio | 19.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-34.42%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-5.2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-93.89%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y